Handbook of Schizophrenia: Neurochemistry and Neuropharmacology of Schizophrenia v. 2

Introduction (F.A. Henn, Stony Brook, NY, and L.E. DeLisi, Bethesda, MD). 1. A historical perspective to the chemistry and pharmacological treatment of schizophrenia (A. Carlsson, Goteborg, Sweden). 2. Two syndromes of schizophrenia as one pole of the continuum of psychosis: a conflict of the nature of the pathogen and its genomic locus (T.J. Crow, Harrow, UK). 3. Neuroanatomical localization of dopamine in the brain and spinal cord (O. Lindvall and A. Bjorklund, Lund, Sweden). 4. Pharmacology of central dopaminergic neurons (M.E. Wolf, Detroit, MI, A.Y. Deutch and R.H. Roth, New Haven, CT). 5. Central dopaminergic systems: neurophysiology and electrophysiological pharmacology (B.S. Bunney and S.R. Sesack, New Haven, CT). 6. Neuroleptic treatment of schizophrenia (J.M. Kane, Glen Oaks, NY). 7. New pharmacological treatments for schizophrenia (J.M. Cott, and N.M. Kurtz Wallingsord, CT). 8. Norepinephrine metabolism in schizophrenia (C.R. Lake, Bethesda, MD, J. Kleinman, Washington, DC, M.S. Kafka, Rockville, MD, G. Ko, Seattle, WA, S. Smith Moore, Bethesda, MD, and M. Ziegler, San Diego, CA). 9. Indoleamines and schizophrenia (S.M. Stahl, Harlow, UK, and K. Wets, London, UK). 10. The role of neuroleptics in schizophrenia (C.B. Nemeroff and G. Bissette, Durham, NC). 11. Phospholipids and prostaglandins in schizophrenia (D. Brody, A. Wolkin and J. Rotrosen, New York, NY). 12. The neuroendocrinology of schizophrenia (P. Powchik, B.M. Davis and K.L. Davis, Bronx, NY). 13. Endogenous hallucinogens and other behavioral modifying factors in schizophrenia (L.E. DeLisi and R.J. Wyatt, Bethesda, MD). 14. Pharmacological models of schizophrenia (B. Angrist, New York, NY). 15. Tardive dyskinesia and schizophrenic burnout: the possible involvement of cytotoxic free radicals (J.L. Cadet, J.B. Lohr and D.V. Jeste, Washington, DC). 16. Neurological disorders and schizophrenia (M. Trimble and D. Rogers, London, UK). 17. Genetic aspects of the biology of schizophrenia (L.R. Goldin, L.E. DeLisi, and E.S. Gershon, Bethesda, MD). 18. Conclusion (F.A. Henn, Stony Brook, NY and L.E. DeLisi, Bethesda, MD). Subject index.